Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS



  • Two different brand names were FDA approved in 2018
    • Krintafel™- radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P. vivax infection.
      • Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
    • Arakoda™-prophylaxis of malaria in patients ≥18 years of age

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: July 3, 2020